Pulmonary embolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: a narrative review
Top Cited Papers
Open Access
- 16 September 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Annals of Intensive Care
- Vol. 10 (1), 1-13
- https://doi.org/10.1186/s13613-020-00741-0
Abstract
Preliminary reports have described significant procoagulant events in patients with coronavirus disease-2019 (COVID-19), including life-threatening pulmonary embolism (PE). We review the current data on the epidemiology, the possible underlying pathophysiologic mechanisms, and the therapeutic implications of PE in relation to COVID-19. The incidence of PE is reported to be around 2.6–8.9% of COVID-19 in hospitalized patients and up to one-third of those requiring intensive care unit (ICU) admission, despite standard prophylactic anticoagulation. This may be explained by direct and indirect pathologic consequences of COVID-19, complement activation, cytokine release, endothelial dysfunction, and interactions between different types of blood cells. Thromboprophylaxis should be started in all patients with suspected or confirmed COVID-19 admitted to the hospital. The use of an intermediate therapeutic dose of low molecular weight (LMWH) or unfractionated heparin can be considered on an individual basis in patients with multiple risk factors for venous thromboembolism, including critically ill patients admitted to the ICU. Decisions about extending prophylaxis with LMWH after hospital discharge should be made after balancing the reduced risk of venous thromboembolism (VTE) with the risk of increased bleeding events and should be continued for 7–14 days after hospital discharge or in the pre-hospital phase in case of pre-existing or persisting VTE risk factors. Therapeutic anticoagulation is the cornerstone in the management of patients with PE. Selection of an appropriate agent and correct dosing requires consideration of underlying comorbidities.Keywords
Funding Information
- Projekt DEAL
This publication has 87 references indexed in Scilit:
- American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapyBlood Advances, 2018
- Coagulation factor XII in thrombosis and inflammationBlood, 2018
- Enoxaparin 40 mg per Day Is Inadequate for Venous Thromboembolism Prophylaxis After Thoracic Surgical ProcedureThe Annals of Thoracic Surgery, 2018
- Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKDAmerican Journal of Kidney Diseases, 2017
- Early Detection of Disseminated Intravascular Coagulation During Septic Shock: A Multicenter Prospective StudyCritical Care Medicine, 2016
- Antithrombotic Therapy for VTE DiseaseSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2016
- Emerging roles for platelets as immune and inflammatory cellsBlood, 2014
- Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatientsThrombosis and Haemostasis, 2014
- Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndromeJournal of Thrombosis and Haemostasis, 2012
- Analysis of thrombotic factors in severe acute respiratory syndrome (SARS) patientsThrombosis and Haemostasis, 2006